Balsalazide Alternatives Compared
Balsalazide | Vedolizumab | Ustekinumab |
|
---|
Balsalazide | Vedolizumab | Ustekinumab |
|
|||||||
---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Ulcerative Colitis, Ulcerative Colitis - Active. Balsalazide may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Ulcerative Colitis, Crohn's Disease - Maintenance, Crohn's Disease. Vedolizumab may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Crohn's Disease - Active, Crohn's Disease, Psoriasis, Plaque Psoriasis, Psoriatic Arthritis, Ulcerative Colitis, Ulcerative Colitis - Active. Ustekinumab may also be used for purposes... View more |
Related suggestions Ulcerative Colitis
|
|||||||
More about Balsalazide | More about Vedolizumab | More about Ustekinumab | ||||||||
Ratings & Reviews | ||||||||||
Balsalazide has an average rating of 6.5 out of 10 from a total of 37 ratings on Drugs.com. 58% of reviewers reported a positive effect, while 28% reported a negative effect. |
Vedolizumab has an average rating of 6.3 out of 10 from a total of 184 ratings on Drugs.com. 49% of reviewers reported a positive effect, while 27% reported a negative effect. |
Ustekinumab has an average rating of 7.5 out of 10 from a total of 266 ratings on Drugs.com. 69% of reviewers reported a positive effect, while 17% reported a negative effect. |
||||||||
Drug Class | ||||||||||
Side Effects | ||||||||||
Generic Availability | ||||||||||
Lower cost generic |
N/A |
N/A |
||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||
View all Balsalazide prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
Dosage Forms Available | ||||||||||
|
N/A |
N/A |
||||||||
Brand Names | ||||||||||
Colazal | Entyvio, Entyvio Pen | Imuldosa, Otulfi, Pyzchiva, Selarsdi, Stelara, Steqeyma, Wezlana, Yesintek | ||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||
N/A |
600 hours |
1291.2 hours |
||||||||
CSA Schedule ** View glossary of terms | ||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
Pregnancy Category | ||||||||||
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||
Drug Interactions | ||||||||||
A total of 171 drugs are known to interact with Balsalazide:
|
A total of 159 drugs are known to interact with Vedolizumab:
|
A total of 529 drugs are known to interact with Ustekinumab:
|
||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
Disease Interactions | ||||||||||
First Approval Date | ||||||||||
July 18, 2000 |
May 20, 2014 |
September 25, 2009 |
||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||
N/A |
N/A |
N/A |
||||||||
More Information | ||||||||||
Patient resources | ||||||||||
Professional Resources | ||||||||||
Related Treatment Guide | ||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.